Moleculin Biotech EBITDA vs. Debt To Equity
| MBRX Stock | USD 2.62 0.03 1.13% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -29.5 M | Current Value -28 M | Quarterly Volatility 12.1 M |
For Moleculin Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Moleculin Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Moleculin Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Moleculin Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Moleculin Biotech over time as well as its relative position and ranking within its peers.
Moleculin |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (12.04) | Return On Assets (0.57) | Return On Equity (1.41) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Moleculin Biotech Debt To Equity vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth. Moleculin Biotech is regarded fourth in ebitda category among its peers. It also is regarded fourth in debt to equity category among its peers . Moleculin Biotech reported EBITDA of (29.5 Million) in 2023. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.Moleculin Debt To Equity vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Moleculin Biotech |
| = | (29.5 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Moleculin Biotech |
| = | 0.01 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Moleculin Debt To Equity Comparison
Moleculin Biotech is currently under evaluation in debt to equity category among its peers.
Moleculin Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Moleculin Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Moleculin Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Moleculin Biotech's change in net profit over the period of time. It can combine multiple indicators of Moleculin Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -9 K | -8.6 K | |
| Interest Income | 1.2 M | 965.1 K | |
| Operating Income | -29.6 M | -28.1 M | |
| Net Loss | -26.3 M | -25 M | |
| Income Before Tax | -29.8 M | -28.3 M | |
| Total Other Income Expense Net | -138 K | -131.1 K | |
| Net Loss | -14.3 M | -15 M | |
| Net Loss | -29.8 M | -28.3 M | |
| Income Tax Expense | -1.5 M | -1.5 M | |
| Net Interest Income | 1.2 M | 1.3 M | |
| Non Operating Income Net Other | 2.7 M | 1.9 M | |
| Change To Netincome | -3.8 M | -3.6 M | |
| Net Loss | (15.07) | (15.82) | |
| Income Quality | 0.81 | 0.76 | |
| Net Income Per E B T | 1.09 | 0.92 |
Moleculin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Moleculin Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Moleculin Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Moleculin Biotech's important profitability drivers and their relationship over time.
Use Moleculin Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Moleculin Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will appreciate offsetting losses from the drop in the long position's value.Moleculin Biotech Pair Trading
Moleculin Biotech Pair Trading Analysis
The ability to find closely correlated positions to Moleculin Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Moleculin Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Moleculin Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Moleculin Biotech to buy it.
The correlation of Moleculin Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Moleculin Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Moleculin Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Moleculin Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Moleculin Biotech position
In addition to having Moleculin Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Funds Thematic Idea Now
Healthcare Funds
Funds or Etfs investing in medical and healthcare goods or services as well as hospital management or maintenance organizations. The Healthcare Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.